<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02938585</url>
  </required_header>
  <id_info>
    <org_study_id>NN7008-4028</org_study_id>
    <secondary_id>U1111-1150-0765</secondary_id>
    <secondary_id>CTR20160811</secondary_id>
    <secondary_id>2013-004791-35</secondary_id>
    <nct_id>NCT02938585</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A.</brief_title>
  <acronym>guardian TM 7</acronym>
  <official_title>Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in China. The aim of this trial is to evaluate the clinical efficacy
      of turoctocog alfa in treatment of bleeding episodes in Chinese patients with severe
      haemophilia A (FVIII≤1%).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 12, 2016</start_date>
  <completion_date type="Anticipated">December 14, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 11, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Haemostatic effect of turoctocog alfa (none, moderate, good or excellent) in treatment of bleeds</measure>
    <time_frame>24 months</time_frame>
    <description>Haemostatic effect of turoctocog alfa when used for treatment of bleeds, assessed on a fourpoint scale for haemostatic response (excellent, good, moderate and none) during the trial period of 24 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of inhibitory antibodies against FVIII</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence rate of inhibitory antibodies against FVIII (≥0.6 Bethesda unit (BU)) during the trial period of 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of bleeds (total bleeds assessed as annual bleeding rate) per patient</measure>
    <time_frame>24 months</time_frame>
    <description>Number of bleeds (total bleeds assessed as annual bleeding rate) per patient during the trial period of 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of turoctocog alfa for bleeding treatment</measure>
    <time_frame>24 months</time_frame>
    <description>Consumption of turoctocog alfa for bleeding treatment (average dose to treat a bleed, number of injections and IU/kg per bleed)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of turoctocog alfa during prophylaxis treatment</measure>
    <time_frame>24 months</time_frame>
    <description>Consumption of turoctocog alfa during prophylaxis treatment (average prophylaxis dose and IU/kg per month and per year) per patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total consumption of turoctocog alfa</measure>
    <time_frame>24 months</time_frame>
    <description>Total consumption of turoctocog alfa (IU/kg per month and per year) per patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>24 months</time_frame>
    <description>Frequency of adverse events (AEs) and serious adverse events (SAEs) reported during the trial period of 24 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Congenital Bleeding Disorder</condition>
  <condition>Haemophilia A</condition>
  <arm_group>
    <arm_group_label>Prophylactic treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>On-demand treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>turoctocog alfa</intervention_name>
    <description>The preventative treatment is administered intravenously (i.v.) at specific intervals either every second day or three times a week. Bleeding treatment will be administered if a bleed should occur.</description>
    <arm_group_label>Prophylactic treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>turoctocog alfa</intervention_name>
    <description>Treatment is administered intravenously (i.v.) during bleeds and occasionally as a preventative treatment (e.g. before physical activity)</description>
    <arm_group_label>On-demand treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients

          -  Age from 0 years

          -  With the diagnosis of severe congenital haemophilia A (FVIII≤1%)

          -  History of exposure days (ED) to any FVIII products fulfilling the criteria of
             previously treated patients:

          -  Patients of 12 years or above: 100 exposures days (ED) or more

          -  Patients below 12 years: 50 exposure days (ED) or more

        Exclusion Criteria:

          -  Inhibitors to factor VIII (≥0.6 BU) at screening as assessed by central laboratory

          -  Known history of FVIII inhibitors
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100045</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chonqqing</city>
        <state>Chongqing</state>
        <zip>400014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Xining</city>
        <state>Qinghai</state>
        <zip>810007</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tianjing</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2016</study_first_submitted>
  <study_first_submitted_qc>October 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2016</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

